New horizons in pharmacotherapy for Cushing’s disease and acromegaly
Endocrine-Related Cancer · 01.11.2026 · 33 (11)
DOI: 10.1530/erc-26-0317 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, online erschienen am 15.10.2026. Verfasst von Maria Fleseriu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University , Portland, Oregon, USA. Hauptthemen laut MEDLINE: Acromegaly, Pituitary ACTH Hypersecretion. Die Arbeit nennt 77 Literaturangaben.
Abstract (Originalsprache)
The recent development of new medical therapies has transformed the Cushing’s disease and acromegaly management, offering patients more individualized and effective treatment strategies beyond surgery and addressing unmet clinical needs in persistent disease. In Cushing’s disease, newer steroidogenesis inhibitors, pituitary-directed therapies, and glucocorticoid receptor antagonists coupled with increasing recognition of disease heterogeneity have highlighted the importance of individualized therapy selection based on corticotroph adenoma characteristics, severity of hypercortisolism, comorbidities, and patient-specific priorities. Management strategies increasingly focus on normalization of biochemical markers, improvement in quality of life and metabolic outcomes, cardiovascular risk reduction, and prolongation of long-term remission. In acromegaly, the medical treatment landscape has expanded beyond monthly injectable and/or oral somatostatin receptor ligands and pegvisomant to include newer octreotide formulations, selective oral somatostatin receptor agonists, combination approaches, and a highly targeted growth hormone receptor antagonist. These developments have enabled improved biochemical control, patient convenience, and long-term disease management. Nevertheless, unmet challenges to optimal management include delayed diagnosis, treatment resistance, adverse drug effects, adenoma recurrence, and the burden of chronic disease monitoring. For both disorders, ongoing clinical trials and emerging precision medicine approaches are refining therapeutic algorithms and offering optimism for further improvements in patient outcomes. This review focuses on newly approved and investigational medical treatments for acromegaly and Cushing’s disease and their evolving role in pituitary care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University , Portland, Oregon, USA.
- Pituitary Center, Department of Medicine, Cedars-Sinai Health Sciences University , Los Angeles, California, USA.
ORCID-Profile: Maria Fleseriu, Shlomo Melmed, Artak Labadzhyan
Zitieren
APA
Fleseriu, M., Melmed, S., & Labadzhyan, A. (2026). New horizons in pharmacotherapy for Cushing’s disease and acromegaly. Endocrine-Related Cancer, 33(11). https://doi.org/10.1530/erc-26-0317
Vancouver
Fleseriu M, Melmed S, Labadzhyan A. New horizons in pharmacotherapy for Cushing’s disease and acromegaly. Endocrine-Related Cancer. 2026;33(11). doi:10.1530/erc-26-0317
BibTeX
@article{Fleseriu2026,
author = {Fleseriu, Maria and Melmed, Shlomo and Labadzhyan, Artak},
title = {New horizons in pharmacotherapy for Cushing’s disease and acromegaly},
journal = {Endocrine-Related Cancer},
year = {2026},
volume = {33},
number = {11},
doi = {10.1530/erc-26-0317}
}
EUVIMED